Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
TransCode Therapeutics, Inc.
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
June 8, 2026
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
June 3, 2026
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
May 27, 2026
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
April 27, 2026
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company’s Runway into Late 2027/Early 2028
April 7, 2026
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
February 8, 2026
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
January 6, 2026
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
December 22, 2025
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode’s Phase 1 trial
December 12, 2025